Delta Global Management LP Invests $2.16 Million in Insulet Corporation $PODD

Delta Global Management LP bought a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,273 shares of the medical instruments supplier’s stock, valued at approximately $2,156,000.

A number of other hedge funds have also added to or reduced their stakes in PODD. Larson Financial Group LLC increased its stake in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the 4th quarter worth about $26,000. DV Equities LLC acquired a new position in shares of Insulet during the 4th quarter worth about $28,000. Elyxium Wealth LLC bought a new position in shares of Insulet in the 4th quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of Insulet in the 4th quarter valued at about $29,000.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PODD shares. UBS Group set a $219.00 target price on Insulet in a report on Thursday, June 11th. Jefferies Financial Group decreased their price target on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Stifel Nicolaus lowered their price target on Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Truist Financial dropped their price objective on Insulet from $219.00 to $210.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Finally, Weiss Ratings downgraded Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $235.25.

Insulet Price Performance

NASDAQ:PODD opened at $163.26 on Friday. The company has a market cap of $11.31 billion, a P/E ratio of 37.97, a P/E/G ratio of 1.14 and a beta of 1.11. The firm’s fifty day moving average price is $154.09 and its two-hundred day moving average price is $202.61. Insulet Corporation has a one year low of $138.79 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.36% of the stock is currently owned by corporate insiders.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: No meaningful positive company-specific catalysts were reported in the latest batch of news.
• Neutral Sentiment: Short-interest data showed 0 shares reported short as of July 24, with a 0.0-day days-to-cover ratio, offering little actionable insight from that update.
• Negative Sentiment: Multiple law firms, including Rosen, Schall, Glancy Prongay, Pomerantz, Bernstein Liebhard, Faruqi & Faruqi, and others, announced or promoted securities class actions against Insulet, which can weigh on investor confidence. Article link
• Negative Sentiment: The lawsuits allege Insulet made misleading statements about manufacturing quality and safety issues, including problems at its Acton facility and flawed pods, suggesting potential reputational and legal overhang for the stock. Article link

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.